Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose versus standard-dose efavirenz with Truvada for treatment-naive HIV-1 infection
ACTRN12610001097033Phase 3Active, not recruiting
- Sponsor
- The Kirby Institute
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised trial of efavirenz, tenofovir and emtricitabine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by The Kirby Institute. Primary endpoint: Proportion with HIV RNA <200 copies/mL at 96 weeks. Started Aug 2011; status: active, not recruiting.
02
Drugs
efavirenztenofoviremtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ACTRN12610001097033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610001097033.